-SYMDEKO is now approved for patients 6 years of age and older with two copies of the F508del mutation or one copy of a responsive mutation--Vertex's third medicine approved to treat the underlying cause of CF in eligible patients in this age range-

https://investors.vrtx.com/press-releases